Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00081042 · ClinicalTrials.gov registry record · Phase 2
ABI-007 in Treating Patients With Inoperable Locally Recurrent or Metastatic Melanoma
A Phase 2 study, sponsored by Jonsson Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00081042 is a Phase 2 study that has completed, run by Jonsson Comprehensive Cancer Center.
The verdict
NCT00081042, a Phase 2 study, has completed, sponsored by Jonsson Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy, such as ABI-007, work in different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase II trial is studying how well ABI-007 works in treating patients with inoperable (unresectable) locally recurrent or metastatic melanoma.
Interventions
- DRUG paclitaxel albumin-stabilized nanoparticle formulation
Trial Details
| Field | Value |
|---|---|
| Start Date | 2004-02 |
| Est. Completion | 2010-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00081042
The ClinicalTrials.gov registry entry for NCT00081042 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Jonsson Comprehensive Cancer Center, which has 321 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which paclitaxel albumin-stabilized nanoparticle formulation is the first listed.
NCT00081042 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00081042 about?
NCT00081042 is a clinical study titled "ABI-007 in Treating Patients With Inoperable Locally Recurrent or Metastatic Melanoma". RATIONALE: Drugs used in chemotherapy, such as ABI-007, work in different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase II trial is studying how well ABI-007 works in treating patients with inoperable (unresectable) locally recurrent or metastatic melanoma.
What is the current status of trial NCT00081042?
This trial is currently completed. It is a Phase 2 study. The study started on 2004-02. Estimated completion is 2010-01.
What interventions are being tested in trial NCT00081042?
The interventions under investigation include: paclitaxel albumin-stabilized nanoparticle formulation (DRUG).
Who is sponsoring clinical trial NCT00081042?
This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.